-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the support of a series of favorable policies such as the acceleration of new drug approval and review, as well as the increase in capital, the number of companies deploying innovative drugs has increased, and domestic innovative drugs have shown a blowout trend in both type and quantity
.
However, for innovative drug products, after the product is launched, it still needs to face the challenge of commercialization.
How to make the innovative drug quickly cover the market terminal is the bottleneck that the development of innovative drug companies urgently needs to break through
.
In order to accelerate the commercialization of innovative drugs, many pharmaceutical companies will choose to join forces to achieve a win-win situation
.
Just recently, Baheal Pharma announced that it will "join hands" with Shanghai Yizhong, and the two sides will cooperate on the commercialization of Zisheng, an innovative tumor drug under Shanghai Yizhong, "Paclitaxel Polymeric Micellar for Injection" ("Paclitaxel Micellar" for short)
.
Paclitaxel products are the cornerstone drugs for anti-tumor chemotherapy, with a wide range of indications, precise curative effects, and large clinical needs
.
Zisheng®, the "paclitaxel polymer micelle for injection" independently developed by Shanghai Yizhong, is a new dosage form of 2.
2 third-generation paclitaxel approved by the State Food and Drug Administration (an innovative dosage form that has not been marketed at home and abroad), and it is also the first domestic drug product.
One of the approved paclitaxel micelles
.
The product was approved for marketing on October 26, 2021, for the treatment of non-small cell lung cancer (NSCLC)
.
It is understood that paclitaxel micelles, as a new preparation of paclitaxel, use a new technology that combines nanotechnology and biomedical polymer material synthesis technology
.
Compared with other paclitaxel dosage forms on the market, paclitaxel micelles have the advantages of in vivo stability and high sensitivity of intratumor drug release when the clinical dose is greatly increased, and have the advantages of better safety and convenient clinical use
.
In addition, the clinical trial results for non-small cell lung cancer (NSCLC) showed that the objective response rate (ORR) of paclitaxel micelles was significantly improved, and the progression-free survival (PFS) was significantly prolonged
.
In the first-line treatment of advanced non-small cell lung cancer, this product shows its unique advantages in terms of efficacy and safety.
It is a major breakthrough in the field of chemotherapy in the past 20 years and is expected to become a new choice for non-small cell lung cancer chemotherapy drugs.
.
Shanghai Yizhong is mainly engaged in the R&D and industrialization of new and improved anti-tumor drugs.
Its core product is Paclitaxel micelles for injection
.
Baheal Pharmaceuticals, which cooperated with Shanghai Yizhong this time, is a professional health brand commercialization platform.
Based on the three core capabilities of "brand operation with category insight, customer management on a full-data platform, and a mechanism to support long-term operation", the company provides innovative Pharmaceutical companies provide professional brand commercialization escort services, empower innovative drug products to quickly enter application scenarios, and break the commercialization dilemma of innovative drugs after they are launched
.
At present, Baheal Pharmaceuticals has brand advantages in the fields of OTC, big health, OTX and other prescription drugs.
Its cooperative customer products include Xeloda and Tarceva from Roche, and Bertanley from Astellas
.
It is reported that in the next step, Baheal Pharmaceuticals will make a good configuration of elements according to the characteristics of the product life cycle, formulate reasonable commercialization solutions, and help the product release value
.
It is worth mentioning that Shanghai Yizhong's paclitaxel polymer micelles for injection missed the opportunity to participate in the 2021 national medical insurance negotiation due to the late approval time
.
As for whether it can enter the medical insurance catalog in 2022, it remains to be seen
.
.
However, for innovative drug products, after the product is launched, it still needs to face the challenge of commercialization.
How to make the innovative drug quickly cover the market terminal is the bottleneck that the development of innovative drug companies urgently needs to break through
.
In order to accelerate the commercialization of innovative drugs, many pharmaceutical companies will choose to join forces to achieve a win-win situation
.
Just recently, Baheal Pharma announced that it will "join hands" with Shanghai Yizhong, and the two sides will cooperate on the commercialization of Zisheng, an innovative tumor drug under Shanghai Yizhong, "Paclitaxel Polymeric Micellar for Injection" ("Paclitaxel Micellar" for short)
.
Paclitaxel products are the cornerstone drugs for anti-tumor chemotherapy, with a wide range of indications, precise curative effects, and large clinical needs
.
Zisheng®, the "paclitaxel polymer micelle for injection" independently developed by Shanghai Yizhong, is a new dosage form of 2.
2 third-generation paclitaxel approved by the State Food and Drug Administration (an innovative dosage form that has not been marketed at home and abroad), and it is also the first domestic drug product.
One of the approved paclitaxel micelles
.
The product was approved for marketing on October 26, 2021, for the treatment of non-small cell lung cancer (NSCLC)
.
It is understood that paclitaxel micelles, as a new preparation of paclitaxel, use a new technology that combines nanotechnology and biomedical polymer material synthesis technology
.
Compared with other paclitaxel dosage forms on the market, paclitaxel micelles have the advantages of in vivo stability and high sensitivity of intratumor drug release when the clinical dose is greatly increased, and have the advantages of better safety and convenient clinical use
.
In addition, the clinical trial results for non-small cell lung cancer (NSCLC) showed that the objective response rate (ORR) of paclitaxel micelles was significantly improved, and the progression-free survival (PFS) was significantly prolonged
.
In the first-line treatment of advanced non-small cell lung cancer, this product shows its unique advantages in terms of efficacy and safety.
It is a major breakthrough in the field of chemotherapy in the past 20 years and is expected to become a new choice for non-small cell lung cancer chemotherapy drugs.
.
Shanghai Yizhong is mainly engaged in the R&D and industrialization of new and improved anti-tumor drugs.
Its core product is Paclitaxel micelles for injection
.
Baheal Pharmaceuticals, which cooperated with Shanghai Yizhong this time, is a professional health brand commercialization platform.
Based on the three core capabilities of "brand operation with category insight, customer management on a full-data platform, and a mechanism to support long-term operation", the company provides innovative Pharmaceutical companies provide professional brand commercialization escort services, empower innovative drug products to quickly enter application scenarios, and break the commercialization dilemma of innovative drugs after they are launched
.
At present, Baheal Pharmaceuticals has brand advantages in the fields of OTC, big health, OTX and other prescription drugs.
Its cooperative customer products include Xeloda and Tarceva from Roche, and Bertanley from Astellas
.
It is reported that in the next step, Baheal Pharmaceuticals will make a good configuration of elements according to the characteristics of the product life cycle, formulate reasonable commercialization solutions, and help the product release value
.
It is worth mentioning that Shanghai Yizhong's paclitaxel polymer micelles for injection missed the opportunity to participate in the 2021 national medical insurance negotiation due to the late approval time
.
As for whether it can enter the medical insurance catalog in 2022, it remains to be seen
.
